WoundReference improves clinical decisions
 Choose the role that best describes you
Cummins DL, Anhalt GJ, Monahan T, Meyerle JH, et al.
The British journal of dermatology. Date of publication 2007 Dec 1;volume 157(6):1235-9.
1. Br J Dermatol. 2007 Dec;157(6):1235-9. Epub 2007 Oct 4. Treatment of pyoderma gangrenosum with intravenous immunoglobulin. Cummins DL(1), Anhalt GJ, Monahan T, Meyerle JH. Author information: (1)Department of Dermatology, Johns Hopkins Medical Institutions, 601 North Caroline Street, Suite 6042, Baltimore, MD 21287, USA. Comment in Br J Dermatol. 2008 Apr;158(4):856-7. BACKGROUND: Intravenous immunoglobulin (IVIG) is increasingly being used to treat inflammatory and autoimmune disease. OBJECTIVES: To elucidate the efficacy of IVIG as an adjunct treatment for pyoderma gangrenosum (PG). PATIENTS/METHODS: Ten patients with PG were treated with IVIG at Johns Hopkins Department of Dermatology. All patients had severe mutilating and/or refractory disease requiring multi-agent therapy. The charts were reviewed retrospectively. RESULTS: Seven of the ten patients had clearance of PG lesions in the setting of IVIG and six of these patients maintained efficacy with repeated IVIG treatment. Five patients complained of nausea with treatment, and in one case nausea was severe and intractable. One patient developed an immune reaction requiring diphenhydramine and methylprednisolone and another experienced aseptic meningitis. CONCLUSIONS: IVIG may be an effective adjuvant in the treatment of PG and has an acceptable side-effect profile. Randomized, placebo-controlled, double-blinded trials are needed to confirm this hypothesis. DOI: 10.1111/j.1365-2133.2007.08217.x PMID: 17916196 [Indexed for MEDLINE]
Appears in following Topics:
Pyoderma Gangrenosum - Treatment